Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients

被引：30

作者：

Watson N.F.S. ^{[1
,2
]}

Madjd Z. ^{[1
]}

Scrimegour D. ^{[1
]}

Spendlove I. ^{[1
]}

Ellis I.O. ^{[3
]}

Scholefield J.H. ^{[2
]}

Durrant L.G. ^{[1
]}

机构：

[1] Academic Department of Clinical Oncology, University of Nottingham, City Hospital

[2] Section of Gastrointestinal Surgery, University of Nottingham, Queens' Medical Centre

[3] Department of Pathology, City Hospital

来源：

World Journal of Surgical Oncology | / 3卷 / 1期

关键词：

Colorectal Cancer; Disease Specific Survival; Early Stage Tumour; Molecular Prognostic Marker; Normal Swine Serum;

D O I：

10.1186/1477-7819-3-47

中图分类号：

学科分类号：

摘要：

Background: Advances in our understanding of the molecular biology of colorectal cancer have fuelled the search for novel molecular prognostic markers to complement existing staging systems. Markers assessed in combination may perform better than those considered individually. Using high-throughput tissue microarray technology, we describe the prognostic value of combined p53/Bcl-2 status in colorectal cancer. Patients and methods: Tumour samples from 462 patients who underwent elective surgery to resect a primary colorectal cancer between 1994 and 2000 (mean follow-up of 75 months) were assembled in tissue microarray format. Clinico-pathological data including tumour grade, stage, vascular invasion status along with disease specific survival data has been collected prospectively. Immunohistochemical analysis of p53 and Bcl-2 expression was performed using antibodies DO-7 (p53) and 124 (Bcl-2), and results correlated with known clinico-pathological variables and outcomes. Results: Abnormal nuclear p53 accumulation and Bcl-2 overexpression were detected in 221/445 (49.6%) and 199/437 (45.5%) tumours respectively, with a significant inverse correlation between the two markers (p = 0.023). On univariate analysis no correlations were found between either marker and standard clinico-pathologicall variables, however nuclear p53 expression was associated with a significantly reduced survival (p = 0.024). Combined analysis of the two markers indicated that 112/432 (24.2%) cases displayed a p53(-)/Bcl-2(+) phenotype, this occurring more frequently in earlier stage tumours. Kaplan-Meier analysis revealed a significant survival advantage in these p53(-)/Bcl-2(+) tumours compared with the remaining cases (p = 0.0032). On multivariate analysis using the Cox proportional hazards model, neither p53 expression nor Bcl-2 expression alone were of independent prognostic significance, however the combined p53(-)/Bcl-2(+) phenotype was significantly associated with a good prognosis in this series (HR 0.659, 95%Cl 0.452-0.959, p = 0.029). Conclusion: Patient stratification by combined p53 / Bcl-2 phenotype provides stage-independent prognostic information in colorectal cancer. Specifically, that up to a quarter of patients display a good prognosis p53(-)/Bcl-2(+) phenotype. This may indicate a more clinically indolent phenotype and a subset of patients for whom less aggressive adjuvant treatment appropriate. © 2005 Watson et al; license BioMed Central Ltd.

引用

页数：10

共 33 条

[1]

Parkin D.M., Global cancer statistics in the year 2000, Lancet Oncol., 2, pp. 533-543, (2001)

[2]

Manne U., Myers R.B., Moron C., Pozatek R.B., Dillard S., Weiss H., Brown D., Srivastava S., Grizzle W.E., Prognostic significance of Bcl-2 expression and nuclear p53 accumulation in colorectal adenocarcinoma, Int. J. Cancer (Pred. Oncol.), 74, pp. 346-358, (1997)

[3]

Manne U., Weiss H.L., Grizzle W.E., Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas, Int. J. Cancer (Pred. Oncol.), 89, pp. 423-430, (2000)

[4]

Schwandner O., Schiedeck T.H.K., Bruch H.P., Duchrow M., Windhoevel U., Broll R., p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer, Eur. J. Cancer, 36, pp. 348-356, (2000)

[5]

Buglioni S., D'Agnano I., Cosimelli M., Vasselli S., D'Angelo C., Tedesco M., Zupi G., Mottolese M., Evaluation of multiple bio-pathological factors in collorectal adenocarcinomas: Independent prognostic role of p53 and Bcl-2, Int. J. Cancer (Pred. Oncol.), 84, pp. 545-552, (1999)

[6]

Baretton G.B., Diebold J., Christoforis G., Vogt M., Muller C., Dopfer K., Schneiderbanger K., Schmidt M., Lohrs U., Apoptosis and immunohistochemical Bc1-2 expression in colorectal adenomas and carcinomas

[7]

Aspects of carcinogenesis and prognostic significance, Cancer, 77, pp. 255-264, (1996)

[8]

Kaklamanis L., Savage A., Whitehouse R., Doussis-Anagnotopoulou I., Biddolph S., Tsiotos P., Mortensen N., Gatter K.C., Harris A.L., Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer, Br. J. Cancer, 77, pp. 1864-1869, (1998)

[9]

Giatromanolaki A., Stathopoulos G.P., Tsiobanou E., Papadimitriou C., Georgoulias V., Gatter K.C., Harris A.L., Koukourakis M.I., Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma, Cancer, 86, pp. 1421-1430, (1999)

[10]

Elkablawy M.A., Maxwell P., Williamson K., Anderson N., Hamilton P.W., Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: Relationship to tumor stage and patient survival, J. Pathol., 194, pp. 436-443, (2001)

← 1 2 3 4 →